Datos Health Partners With Vaica Medical

Augments Remote Care Platform With Medication Management Capabilities

Datos Health, a leader of remote care automation, and Vaica Medical, a leading provider of medication adherence solutions, today announced a partnership to include medication adherence information as part of Datos’ offering of analyzed data relating to the overall status of patients’ health and wellbeing.

The first implementation for this collaboration began in the third quarter of 2020 with the Psychiatry Division at Sheba Medical Center, as part of an overall program to introduce comprehensive remote psychiatric care (i.e. telemedicine) to the home environment.

The partnership between Datos Health and Vaica Medical addresses the general lack of patient adherence to treatments and the challenge this poses by negatively impacting patients’ recovery, resulting in a greater burden on healthcare providers. Vaica’s comprehensive medication adherence technology, synchronized with patient-generated data collated and evaluated by Datos’ remote care platform, enables clinicians to stay up-to-date regarding the status of patients, facilitating enhanced decision making. Concurrently, the Datos mobile app enables more personalized care by ensuring patients are well-informed, take greater responsibility for their own treatments, and remain engaged with their care providers.

“Partnering with Vaica allows us to complement our remote care offerings with a new dimension, furthering our goal of advancing proactive and personalized care through increased patient engagement,” said Uri Bettesh, CEO and Founder of Datos Health. “We look forward to continually expanding our capabilities to support hospitals through remote care initiatives that can ultimately improve patient outcomes.”

Patients found to be suitable for home hospitalization received a specialized kit to maintain continuous contact and online follow-ups with clinical staff. Monitoring devices collate all clinical data for analysis, while the Datos mobile app facilitates video calls with physicians and nurses available on a 24/7 basis. The Datos app further alerts care teams of deviation from routine, including sleep disturbance, changes in mood and – through inclusion of Vaica’s core technology – medication adherence.

“The fundamental goal of this partnership is to improve medication adherence rates among patients through remote care technology, setting the foundation for improved patient-clinician engagement and better-informed treatment,” said Tomer Gofer, CEO for Vaica Medical. “Through our collaboration with Datos, care teams will be able to not only monitor patient adherence to medication in real-time, but also correlate this new layer of information with additional data to fully benefit both patients and providers.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version